相关实验视频
Updated: May 11, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.3K
初级陶病与逻辑/语义混合的渐进性失言症和前性痴呆症类似的行为
Akihiro Takasaki1, Yoshiyuki Nishio2, Yuto Satake1
1Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan.
概括
这项研究详细介绍了两例阿尔茨海默病 (AD) 和前叶退化 (FTLD) 的早期症状. 研究结果表明,一种新型的病综合征与典型的AD不同.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 临床神经学 临床神经学
背景情况:
- 阿尔茨海默病 (AD) 和前叶退化 (FTLD) 是不同的神经退行性疾病.
- 阿尔茨海默病和FTLD之间的早期临床重叠可能会使诊断复杂化.
- 病理与AD和FTLD有关,但具有不同的特征.
研究的目的:
- 描述两个病例,其中AD和FTLD的早期临床症状重叠.
- 为了调查这些病例的潜在神经病理学.
- 提出一种与非阿尔茨海默氏症病相关的潜在新综合征.
主要方法:
- 两个患有复杂神经症状的个体的案例研究.
- 临床评估侧重于语言和行为变化.
- 多模式神经成像 (MRI,PET) 用于评估大脑结构和功能.
- 病理学检查以确定潜在的神经病理学.
主要成果:
- 患者表现出声学缺陷 (暗示AD) 和语义障碍与行为变化 (暗示FTLD).
- 神经成像揭示了具有3/4重复的异形的初级病变.
- 阿尔茨海默病的特征 - - 粉样蛋白沉积显著缺失.
结论:
- 这些发现表明一种以前未被识别的临床综合征.
- 这种综合征似乎与非阿尔茨海默氏症原发性陶病症有关.
- 早期区分AD和FTLD对于准确的诊断和管理至关重要.
相关概念视频
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Dementia
65
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
65
Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Amyloid Fibrils
9.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.0K

